Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyDiseaseAdrenocortical CarcinomaSubgroupICD10C74.0MeSHAdrenocortical CarcinomaSequenceDOXO40/ETOP100/CISP100/MTTN1,5, ACC, C1 (PID2021) -|- DOXO40/ETOP100/CISP100/MTTN1,5, ACC, C2+ (PID1257)STRE1/MTTN1.5, ACC, C1 (PID2012) -|- STRE2/MTTN1.5, ACC, C2+ (PID2020)ChemotherapyChemo-substanceCabozantinibCapecitabineCisplatinDoxorubicinEtoposideGemcitabineMitotanPembrolizumabStreptozocinChemo-substanceCabozantinibCapecitabineCisplatinDoxorubicinEtoposideGemcitabineMitotanPembrolizumabStreptozocinChemo-substanceCabozantinibCapecitabineCisplatinDoxorubicinEtoposideGemcitabineMitotanPembrolizumabStreptozocinChemo-substanceCabozantinibCapecitabineCisplatinDoxorubicinEtoposideGemcitabineMitotanPembrolizumabStreptozocinNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances12468Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseTherapy intentioncurativedisease controlpalliativeRisksAdrenal InsufficiencyAnemia Hb below 8g/dlDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueGynecomastiaHand-Foot SyndromeHepatotoxicityHypercholesterolemiaHyperthyroidismHypoalbuminemiaHypocalcemiaHypokalemiaHypomagnesemiaHypophosphatemiaHypothyroidismIncrease AminotransferasesIncrease in lipaseInfectionsMucositisNauseaNeurotoxicityNeutropeniaProteinuriaThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorCampbell MTFassnacht MRaj NSperone PTerzolo MWilliamson SDiseaseFortgeschrittenes, nicht resezierbares oder metastasiertes Nebennierenrindenkarzinom, ECOG 0-2Fortgeschrittenes Nebennierenrindenkarzinom, ECOG 0-2Fortgeschrittenes Nebennierenrindenkarzinom, Erstlinie, ECOG 0-2Fortgeschrittenes Nebennierenrindenkarzinom, palliativ oder additiv nach ResektionFortgeschrittenes oder metastasiertes adrenokortikales Karzinom, nicht resezierbar, ECOG 0-2Nebennierenrindenkarzinom, ENSAT Stadium I–III, nach R0 Resektion, ECOG 0-2Nebennierenrindenkarzinom, nicht reseziert oder metastasiert, ECOG 0-1OriginDivision of Clinical Oncology, University of Kansas Medical Center, Kansas.Memorial Sloan Kettering Cancer Center, New York, NYOncologia Medica, Dipartimento di Scienze Cliniche e Biologiche Universita`di Torino, Orbassano, ItalySan Luigi Gonzaga Hospital, University of Turin, Turin, Italy, ADIUVO trialThe University of Texas MD Anderson Cancer Center, Houston, USAUniversity of Würzburg, Würzburg, GermanyUniversitätsklinikum Würzburg, Medizinische Klinik I, FIRM-ACT Study GroupProtocols in Revision 10 protocols foundProtocols under revision.Cabozantinib 60, Adrenocortical Carcinoma (PID2625 V1.0)Cisplatin 50 / Etoposide 100, Adrenocortical Carcinoma (PID1369 V1.1)Doxorubicin 40 / Etoposide 100 / Cisplatin 40 / Mitotane 1.5, Adrenocortical Carcinoma, cycle 1 (PID2021 V1.2)Doxorubicin 40 / Etoposide 100 / Cisplatin 40 / Mitotan 1.5, Adrenocortical Carcinoma, Cycle 2+ (PID1257 V1.3)Etoposide 100 / Cisplatin 40 / Mitotan 1.5, Adrenocortical Carcinoma (PID2479 V1.1)Gemcitabine 800 / Capecitabine 750 / Mitotan 1.5, Adrenocortical Carcinoma (PID1024 V1.1)Mitotan 1.5, Adrenocortical Carcinoma, adjuvant (PID2463 V1.1)Pembrolizumab 200, Adrenocortical Carcinoma (PID2484 V1.0)Streptozocin 1 / Mitotane 1.5, Adrenocortical Carcinoma, cycle 1 (PID2012 V1.2)Streptozocin 2 / Mitotane 1.5, Adrenocortical Carcinoma, cycle 2+ (PID2020 V1.2)
